With Nextellis being the Gamechanger ? I just had a reread of past reports. With 60m contraceptive pill prescriptions written annually. Being $3.4b Mayne had 3000+ in December 2021. This from 0 June 21. Growth graph looks good. Positive expansion. I wouldn’t be surprised if 8000/ month attained June 30 EOFY. This being 100,000 scripts/ annum. Maynes outlook was 120,000/annum to achieve 2% market share by volume. This then amounting to $200m / annum net sales. All things being equal and few flys in the ointment. These figures appear quite achievable EOFY 2023. For any would be higher achieving investors too late by then. As should Mayne be positive in all other areas . International; Generic controls; Dermatology; Womens Health; and their Metrics, Next months report may well be the finally announced company turnaround and true blue sky way forward. I really believe Mayne is now a low risk high value BUY !!
MYX Price at posting:
32.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)